Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa
(photo credit: BAZ RATNER/REUTERS)
Six critically ill coronavirus patients in Israel who are considered high-risk for mortality have been treated with Pluristem’s placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.